Fertility drugs and endometrial cancer risk: Results from an extended follow-up of a large infertility cohort

Human Reproduction

Volumn 28, Issue 10, 2013, Pages 2813-2821

  Brinton, Louise A ^a   Westhoff, Carolyn L ^b   Scoccia, Bert ^c   Lamb, Emmet J ^d   Trabert, Britton ^a   Niwa, Shelley ^e   Moghissi, Kamran S ^f  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Columbia University ^*  (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d STANFORD UNIVERSITY   (United States)

^e WESTAT   (United States)

^f WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

clomiphene citrate; endometrial cancer; gonadotrophins; infertility; risk

Indexed keywords

CLOMIFENE; GONADOTROPIN;

ADULT; ARTICLE; CANCER RISK; CANCER SURGERY; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG USE; ENDOMETRIUM CANCER; FEMALE; FEMALE INFERTILITY; FOLLOW UP; HUMAN; HYSTERECTOMY; MAJOR CLINICAL STUDY; QUESTIONNAIRE; RETROSPECTIVE STUDY;

CLOMIPHENE CITRATE; ENDOMETRIAL CANCER; GONADOTROPHINS; INFERTILITY; RISK;

CLOMIPHENE; COHORT STUDIES; ENDOMETRIAL NEOPLASMS; FEMALE; FERTILITY AGENTS, FEMALE; FOLLOW-UP STUDIES; HUMANS; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84885119585     PISSN: 02681161     EISSN: 14602350     Source Type: Journal    
DOI: 10.1093/humrep/det323     Document Type: Article

References (22)

1. Althuis MD, Moghissi KS, Westhoff CL, Scoccia B, Lamb EJ, Lubin JH, Brinton LA. Uterine cancer after use of clomiphene citrate to induce ovulation. Am J Epidemiol 2005;161:607-615.
2. Benshushan A, Paltiel O, Brzezinski A, Tanos V, Barchana M, Shoshani O, Gordon L, Tsur L, Schenker JG. Ovulation induction and risk of endometrial cancer: A pilot study. Eur J Obstet Gynecol Reprod Biol 2001; 98:53-57.
3. Beral V, Bull D, Reeves G. Endometrial cancer and hormone-replacement therapy in the MillionWomen Study. Lancet 2005;365:1543-1551.
4. Brinton LA, Westhoff CL, Scoccia B, Lamb EJ, Althuis MD, Mabie JE, Moghissi KS. Causes of infertility as predictors of subsequent cancer risk. Epidemiology 2005;16:500-507.
5. Brinton LA, Sahasrabuddhe VV, Scoccia B. Fertility drugs and the risk of breast and gynecologic cancers. Semin Reprod Med 2012;30:131-145.
6. Brinton LA, Felix AS, McMeekin DS, CreasmanWT, Sherman ME, Mutch D, Cohn DE, Walker JL, Moore RG, Downs LS et al. Etiologic heterogeneity in endometrial cancer: Evidence from a Gynecologic Oncology Group Trial. Gynecol Oncol 2013a;129:277-284.
7. Brinton LA, Trabert B, Shalev V, Lunenfeld E, Sella T, Chodick G. In vitro fertilization and risk of breast and gynecologic cancers: A retrospective cohort study within the Israeli Maccabi Healthcare Services. Fertil Steril 2013b;99:1189-1196.
8. Calderon-Margalit R, Friedlander Y, Yanetz R, Kleinhaus K, Perrin MC, Manor O, Harlap S, Paltiel O. Cancer risk after exposure to treatments for ovulation induction. Am J Epidemiol 2009;169:365-375.
9. Cox D. Regression models and life tables (with discussion). J Roy Statist Soc B 1972;32:187-220.
10. Cramer DW. The epidemiology of endometrial and ovarian cancer. Hematol Oncol Clin North Am 2012;26:1-12.
11. Derman SG, Adashi EY. Adverse effects of fertility drugs. Drug Saf 1995; 11:408-421.
12. Dor J, Lerner-Geva L, Rabinovici J, Chetrit A, Levran D, Lunenfeld B, Mashiach S, Modan B. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril 2002;77:324-327.
13. dos Santos Silva I, Wark PA, McCormack VA, Mayer D, Overton C, Little V, Nieto J, Hardiman P, DaviesM, MacLean AB. Ovulation-stimulation drugs and cancer risks: A long-term follow-up of a British cohort. Br J Cancer 2009; 100:1824-1831.
14. Doyle P, Maconochie N, Beral V, Swerdlow AJ, Tan SL. Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod 2002; 17:2209-2213.
15. Jensen A, Sharif H, Kjaer SK. Use of fertility drugs and risk of uterine cancer: Results from a large Danish population-based cohort study. Am J Epidemiol 2009;170:1408-1414.
16. Lerner-Geva L, Jaron R, Liraz O, Tzvia B, Shlomo M, Bruno L. Are infertility treatments a potential risk factor for cancer development?. Perspective of 30 years of follow-up. Gynecol Endocrinol 2012;28:809-814.
17. Potashnik G, Lerner-Geva L, Genkin L, Chetrit A, Lunenfeld E, Porath A. Fertility drugs and the risk of breast and ovarian cancers: Results of a long-term follow-up study. Fertil Steril 1999;71:853-859.
18. Setiawan VW, Yang HP, Pike MC, McCann SE, Yu H, Xiang YB, Wolk A, Wentzensen N, Weiss NS, Webb PM et al. Type I and II endometrial cancers: Have they different risk factors?. J Clin Oncol 2013;31:2607-2618.
19. Sovino H, Sir-Petermann T, Devoto L. Clomiphene citrate and ovulation induction. Reprod Biomed Online 2002;4:303-310.
20. Trabert B, Wentzensen N, Yang HP, Sherman ME, Hollenbeck AR, Park Y, Brinton LA. Is estrogen plus progestin menopausal hormone therapy safe with respect to endometrial cancer risk?. Int J Cancer 2013; 132:417-426.
21. Varras M, Polyzos D, Akrivis C. Effects of tamoxifen on the human female genital tract: Review of the literature. Eur J Gynaecol Oncol 2003; 24:258-268.
22. Venn A, Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 1999;354:1586-1590.